How male-level testosterone affects reproductive hormone cycles in people assigned female at birth
Official title: Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version
Run by University of California, San Diego · NCT07092527 · Data updated 2026-11-12
This study will test whether male-level testosterone given to transgender men starting hormone therapy changes the ovarian and pituitary hormones that control menstrual cycles compared with cisgender women.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 35 Years |
| Sex | Women only |
| Enrollment | 80 (estimated) |
| Sponsor | University of California, San Diego Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (San Diego, California) |
| Status | Recruiting |
| Started | December 5, 2025 |
| Main results expected | November 15, 2028 |
| Study ends | November 30, 2028 |
| Registry record updated | January 15, 2026 |
| Trial ID | NCT07092527 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are 18-35 year olds assigned female at birth who have regular menstrual cycles and either plan to start testosterone therapy (transgender/non-binary group) or are cisgender women with regular cycles willing to serve as controls.
✕Probably not a fit
People who are pregnant, incarcerated, have untreated endocrine conditions (including PCOS), extreme BMI (<18 or >35), low hemoglobin, or are outside the 18-35 age range are excluded and would not benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will follow people assigned female at birth who are 18-35 years old, comparing those who plan to start testosterone therapy with untreated cisgender female controls. They will collect frequent blood samples to measure ovarian and pituitary reproductive hormones before and during testosterone cypionate treatment and perform periodic clinical exams and pelvic ultrasounds. The trial excludes people with pregnancy, known endocrine disease (including PCOS), extreme BMI, low hemoglobin, or other specified conditions. Data will characterize how chronic testosterone exposure alters hormone secretion patterns that regulate menstrual cyclicity.
Why it matters
Potential benefit: If successful, results could explain why testosterone causes menstrual changes and help guide safer, more predictable hormone regimens for transgender men.
How similar studies have gone: Clinical observations consistently report menstrual disruption with testosterone therapy, but detailed longitudinal hormonal studies like this are limited, so the approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Transgender/Non-binary Group, Initiating Testosterone Group * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Aged 18-35 * Plan to initiate testosterone therapy * History of regular menstrual cycles (every 24-35 days) at baseline, before beginning TRT Inclusion Criteria: Cisgender Female Group * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Aged 18-35 * Having regular menstrual cycles (every 24-35 days) Exclusion Criteria: All * Pregnant * Incarcerated * Known cognitive impairment or institutionalized * Hemoglobin less than 11 gm/dl at screening evaluation * Weight less than 110 pounds * BMI \<18 or \>35 * Current endocrine disease- including untreated thyroid abnormalities, pituitary or adrenal disease, polycystic ovary syndrome, or androgen producing tumor * Current or recent pregnancy within two months of study enrollment * Current or recent breast feeding within two months of study enrollment * Diabetes, or renal, liver, or heart disease * History of oophorectomy or hysterectomy * History of radiation or surgery involving brain structures and/or pelvis/pelvic organs * Currently taking any medications that may affect their reproductive hormones, such as contraceptive medications, androgens, estrogens, progestins, gonadotropin-releasing hormone (GnRH) antagonists, insulinomimetics, and metformin. * History of prior testosterone therapy
Where it's running
-
University of California, San Diego
San Diego, California, United States Recruiting
Study contacts
- Principal investigator: Antoni Duleba, MD — University of California, San Diego
- Study coordinator: Antoni Duleba, MD
- Email: aduleba@health.ucsd.edu
- Phone: 619-804-4765
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI tool to analyze sperm and predict their ability to help IVF/ICSI succeed
This project will test an AI platform that analyzes semen samples from men providing sperm for IVF/ICSI to see if it can predict which samples have the best chance of supporting successful IVF/ICSI outcomes.
-
Progesterone level on embryo transfer day and pregnancy after frozen embryo transfer
We will test whether blood progesterone levels on the day of embryo transfer affect the chance of clinical pregnancy for people having hormone-replacement frozen-thawed embryo transfers.
-
What factors affect pregnancy success after IUI
This project will try to see if hormone levels on trigger day, follicle and uterine measurements, and sperm quality are linked to the chance of a clinical pregnancy after IUI for couples who had IUI cycles.
-
Evaluating a new method for sperm capacitation
This study is testing a new method called HyperSperm to see if it can improve sperm quality for men who are having trouble with fertility.
-
Comparing Day 5 and Day 6 Embryo Transfers for Pregnancy Rates
This study is testing whether transferring embryos on day 5 or day 6 after treatment can lead to higher pregnancy rates for people undergoing fertility treatment.
-
Evaluating voice outcomes after gender-affirming voice surgeries
This study is testing how different gender-affirming voice surgeries affect voice quality and patient satisfaction over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.